ATH 0.00% 0.3¢ alterity therapeutics limited

Neurodegenerate biomarker testing

  1. 1,374 Posts.
    lightbulb Created with Sketch. 126
    Hi all,

    I came across this presentation this evening discussing upcoming biomarker tests for neurodegenerate diseases.

    A discussion point was relating to NfL, showing a number of diseases had a marked increase in NfL. Given Prof. Classens latest presentation of ATH434 treatment and the significant reduction of NfL compared to those in the biomuse study, it would be incredibly interesting in my view, if ATH434 could be utilised in all these neurodegenate diseases that have elevated NfL readings.

    Abit more to look into, such as how exactly is ATH434 causing such a reduction, but also with such a massive reduction is it preserving axon death, which will no doubt be observed in the 201 study.

    Anyways, hope you enjoy. P.S. I didnt watch the full hour just the neurofilament light section. I will likely watch it all when time allows.

    https://m.youtube.com/watch?v=__ohWnEJuf8
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
0.000(0.00%)
Mkt cap ! $15.96M
Open High Low Value Volume
0.3¢ 0.3¢ 0.3¢ $2.401K 800.3K

Buyers (Bids)

No. Vol. Price($)
77 110142186 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 150940914 62
View Market Depth
Last trade - 10.20am 08/11/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.